PDGFRA
ENSG00000134853
Target class
Kinase
Chromosome
4
Approved drugs
11
Clinical candidates (approved and in development)
31
- Approved drugs
- 11
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 31
- Chemical probe available
- Yes
- Target name
- PDGFRA
- Gene name
- Platelet derived growth factor receptor alpha
- Gene symbol
- PDGFRA
- Protein name
- Platelet-derived growth factor receptor alpha (PDGF-R-alpha) (PDGFR-alpha) (EC 2.7.10.1) (Alpha platelet-derived growth factor receptor) (Alpha-type platelet-derived growth factor receptor) (CD140 antigen-like family member A) (CD140a antigen) (Platelet-derived growth factor alpha receptor) (Platelet-derived growth factor receptor 2) (PDGFR-2) (CD antigen CD140a)
- CD140a
- PDGFR2
- GAS9
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|I-set domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 217.53
- Tissue specificity (Gini)
- 0.526
- Tissue specificity (tau)
- 0.854
- KEGG gene identifiers
- hsa:5156
- Protein interaction confidence
- 0.83331
- Protein interaction partners
- 142
- R-HSA-1257604
- R-HSA-186763
- R-HSA-186797
- R-HSA-2219530
- R-HSA-5673001
- R-HSA-6811558
- R-HSA-9673767
- R-HSA-9673770
- R-HSA-9674396
- R-HSA-9674401
- R-HSA-9674403
- R-HSA-9674404
- R-HSA-9674428
- End position
- 54298246
- Start position
- 54229130
- Chromosome
- 4
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Cell projection, cilium . Golgi apparatus .
- Cell Junctions
- Plasma membrane
- PubMed 14644164
- PubMed 2554309
- PubMed 8188664
- Tissue specificity (tau)
- 0.854478
- Expression inequality (Gini)
- 0.525696
Expression in transcripts per million
- Ovary
- 217.53
- Cells - Cultured fibroblasts
- 164.2
- Cervix - Endocervix
- 100.04
- Fallopian Tube
- 89.11
- Uterus
- 77.46
Expression in transcripts per million
- Ovary217.53
- Cells - Cultured fibroblasts164.2
- Cervix - Endocervix100.04
- Fallopian Tube89.11
- Uterus77.46
- Artery - Aorta68.26
- Bladder66.16
- Spleen61.62
- Artery - Coronary61.21
- Lung60.92
- Vagina58.17
- Cervix - Ectocervix56.03
- Adipose - Visceral (Omentum)54.55
- Colon - Sigmoid52.72
- Adipose - Subcutaneous52.11
- Esophagus - Gastroesophageal Junction52.02
- Breast - Mammary Tissue42.53
- Nerve - Tibial41.97
- Esophagus - Muscularis40.42
- Small Intestine - Terminal Ileum38.01
- Colon - Transverse35.66
- Artery - Tibial34.32
- Thyroid27.91
- Stomach24.67
- Heart - Atrial Appendage21.98
And 29 more, listed on the interactive page.
- GO:0001775
- GO:0008284
- GO:0010544
- GO:0018108
- GO:0030335
- GO:0032956
- GO:0034614
- GO:0035790
- GO:0038091
- GO:0046777
- GO:0048008
- GO:0048146
- GO:0050850
- GO:0050921
- GO:0051897
- GO:0070374
- GO:0070527
- GO:2000739
- GO:0005789
- GO:0005886
- GO:0016020
- GO:0032991
- GO:0004672
- GO:0004714
- GO:0005018
- GO:0005021
- GO:0005161
- GO:0005515
- GO:0038085
- GO:0042803
- GO:0048407
- GO:0160185
Related records
Trials (1,696)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
- (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
Drugs (33)
- Amuvatinib Platelet-derived growth factor receptor alpha inhibitor
- Avapritinib Platelet-derived growth factor receptor alpha inhibitor
- Becaplermin Platelet-derived growth factor receptor agonist
- Cediranib Platelet-derived growth factor receptor inhibitor
- Crenolanib Platelet-derived growth factor receptor inhibitor
- Dovitinib Platelet-derived growth factor receptor inhibitor
- ENMD-981693 Platelet-derived growth factor receptor inhibitor
- Famitinib Platelet-derived growth factor receptor inhibitor
- Foretinib Platelet-derived growth factor receptor inhibitor
- Ilorasertib Platelet-derived growth factor receptor inhibitor
- Linifanib Platelet-derived growth factor receptor inhibitor
- Masitinib Platelet-derived growth factor receptor inhibitor
- Midostaurin Platelet-derived growth factor receptor inhibitor
- Motesanib Platelet-derived growth factor receptor inhibitor
- Nintedanib Platelet-derived growth factor receptor inhibitor
- Nintedanib esylate Platelet-derived growth factor receptor inhibitor
- Olaratumab Platelet-derived growth factor receptor alpha antagonist
- Orantinib Platelet-derived growth factor receptor inhibitor
- Pazopanib Platelet-derived growth factor receptor inhibitor
- Pazopanib hydrochloride Platelet-derived growth factor receptor inhibitor